← back to search

Yehuda Handelsman

Translational Research Institute for Metabolism and Diabetes ·
Area of research
Endocrinology, Diabetes and Metabolism · Physiology
Research interest
Research interests include Diabetes Treatment and Management, Diabetes Management and Research, Diabetes, Cardiovascular Risks, and Lipoproteins, and Diet and metabolism studies.
h-index
65
citations
22,012
works
227
NIH funding
primary concept
Medicine
email

Recent publications

Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes
Diabetes Care 2025cited by 22position: middledoi
Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment
Diabetes Care 2025cited by 14position: middledoi
DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
Metabolism 2024cited by 76position: firstdoi
Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial
BMJ 2024cited by 14position: middledoi
Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases
Journal of Diabetes and its Complications 2023cited by 93position: firstdoi
Cardio‐renal‐metabolic disease in primary care setting
Diabetes/Metabolism Research and Reviews 2023cited by 11position: middledoi
Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements
Expert Review of Cardiovascular Therapy 2022cited by 24position: middledoi
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases
Journal of Diabetes and its Complications 2021cited by 62position: firstdoi
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary
Endocrine Practice 2020cited by 601position: middledoi
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm – 2020 Executive Summary
Endocrine Practice 2020cited by 245position: firstdoi
Use of Sodium–Glucose Co-Transporter-2 Inhibitors in Patients with and without Type 2 Diabetes: Implications for Incident and Prevalent Heart Failure
European Journal of Heart Failure 2020cited by 52position: middledoi
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary
Endocrine Practice 2019cited by 297position: middledoi
Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study
Diabetologia 2019cited by 70position: middledoi
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary
Endocrine Practice 2018cited by 505position: middledoi
Dysglycemia-Based Chronic Disease: An American Association of Clinical Endocrinologists Position Statement
Endocrine Practice 2018cited by 102position: middledoi
American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease
Endocrine Practice 2017cited by 1,095position: middledoi
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
The Lancet Diabetes & Endocrinology 2017cited by 590position: middledoi
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm – 2017 Executive Summary
Endocrine Practice 2017cited by 434position: middledoi
American Association Of Clinical Endocrinologists And American College Of Endocrinology Guidelines For Management Of Dyslipidemia And Prevention Of Cardiovascular Disease - Executive Summary
Endocrine Practice 2017cited by 207position: middledoi
American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Testing for Autonomic And Somatic Nerve Dysfunction
Endocrine Practice 2017cited by 24position: middledoi
Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY
Endocrine Practice 2016cited by 875position: middledoi
Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis
Diabetes 2016cited by 821position: middledoi
American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis
Endocrine Practice 2016cited by 356position: firstdoi
American Association Of Clinical Endocrinologists And American College Of Endocrinology 2016 Outpatient Glucose Monitoring Consensus Statement
Endocrine Practice 2016cited by 124position: middledoi
Transculturalization Recommendations For Developing Latin American Clinical Practice Algorithms In Endocrinology Proceedings Of The 2015 Pan-American Workshop By The American Association Of Clinical Endocrinologists And American College Of Endocrinology
Endocrine Practice 2016cited by 16position: middledoi
American Association of Clinical Endocrinologists and American College of Endocrinology – Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan – 2015 — Executive Summary
Endocrine Practice 2015cited by 633position: firstdoi
American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan – 2015
Endocrine Practice 2015cited by 565position: firstdoi
The CardioMetabolic Health Alliance
Journal of the American College of Cardiology 2015cited by 280position: middledoi
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2015 Executive Summary
Endocrine Practice 2015cited by 54position: middledoi
American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the 2014 Advanced Framework for a New Diagnosis of Obesity as a Chronic Disease
Endocrine Practice 2014cited by 233position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

George Grunberger · Charles University17 papers (2013–2023)Alan J. Garber · Baylor College of Medicine13 papers (2013–2020)Jeffrey I. Mechanick · Mount Sinai Hospital12 papers (2014–2020)Daniel Einhorn · Corcept Therapeutics (United States)11 papers (2013–2020)Guillermo E. Umpierrez · Emory University10 papers (2014–2023)Paul S. Jellinger · Brigham and Women's Hospital9 papers (2015–2020)Zachary T. Bloomgarden · Ruijin Hospital9 papers (2013–2020) · 9 papers (2015–2020)Vivian Fonseca · Tulane University9 papers (2016–2023)Janet B. McGill · University of Colorado Denver8 papers (2014–2020)W. Timothy Garvey · University of Alabama at Birmingham8 papers (2013–2020)Ralph A. DeFronzo · Georgetown University7 papers (2016–2023)Michael A. Bush · Nationwide Children's Hospital7 papers (2015–2020)Irl B. Hirsch · University of Washington7 papers (2015–2020)Samuel Dagogo‐Jack · University of Tennessee Health Science Center7 papers (2014–2019) · 6 papers (2015–2020) · 6 papers (2015–2020)Joshua I. Barzilay · Kaiser Permanente6 papers (2015–2020)Jeffrey R. Garber · Westmead Hospital6 papers (2015–2020)Chantal Mathieu · Centre de recherches juridiques de l'Université de Franche-Comté4 papers (2012–2016)